InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (5 ops.)
Insider track record
CEODisclosed buys
0
Disclosed sells
5
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Browse the full record of transactions filed by Simpson Adam K., Chairman & CEO. Director active across 1 company, notably Icosavax, Inc.. Cumulatively, 19 reports have been published. Split: 0 buy · 5 sells. Total volume traded: €1.6m. History available since 30 July 2021. The latest transaction was filed on 1 February 2024 (Don). Regulator: SEC (Form 4). All data is openly available.
Declarations19 total
358,657 sharesCommon StockSEC:0000950170-24-017431:0
6,532 shares0Common StockSEC:0000950170-24-010798:0
4,789 shares@ US$0.840.1% of flowCommon StockSEC:0001209191-24-002106:0
15,000 shares@ US$1.040.3% of flowCommon StockSEC:0001209191-24-000844:0
62,205 shares@ US$15.457118.1% of flowCommon StockSEC:0001209191-23-059625:0
3,000 shares@ US$0.840.0% of flowCommon StockSEC:0001209191-23-044092:0
11,788 shares@ US$8.86152.0% of flowCommon StockSEC:0001209191-23-044088:0
10,677 shares@ US$1.040.2% of flowCommon StockSEC:0001209191-23-010309:0
7,506 shares@ US$10.69261.6% of flowCommon StockSEC:0001209191-23-009918:0
2,395 shares@ US$0.840.0% of flowCommon StockSEC:0001209191-23-005315:0
66,764 shares@ US$8.96311.6% of flowCommon StockSEC:0001209191-22-062666:0
2,456 shares@ US$7.10760.4% of flowCommon StockSEC:0001209191-22-044025:0
7,185 shares@ US$0.840.1% of flowCommon StockSEC:0001209191-22-041373:0
4,789 shares@ US$0.840.1% of flowCommon StockSEC:0001209191-22-021658:0
75,578 shares0Common StockSEC:0001209191-22-009528:0
16,764 shares@ US$0.840.4% of flowCommon StockSEC:0001209191-22-005478:0
16,764 shares@ US$0.840.3% of flowCommon StockSEC:0001209191-22-005478
125,000 shares@ US$15.0049.6% of flowCommon StockSEC:0000899243-21-031140:0
125,000 shares@ US$15.0032.5% of flowCommon StockSEC:0000899243-21-031140
19 of 19 declarations
About Simpson Adam K.
Simpson Adam K. is the Chief Executive Officer of Icosavax, Inc. In this role, he is responsible for the strategic and operational leadership of the company. His expertise in biopharmaceutical product development and ability to lead teams are essential for achieving Icosavax's growth and innovation objectives.
